Grove Bank & Trust’s Arcus Biosciences RCUS Stock Holding History

Grove Bank & Trust’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-49	Closed	-$880	–	684
2023 Q3	$880	Buy	+49	New	+$985	﹤0.01%	704

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Grove Bank & Trust's RCUS Position: Q4 2023 in Review

Grove Bank & Trust sold out of Arcus Biosciences (RCUS) in Q4 2023, closing a stake of 49 shares — an estimated $880 sold.

Grove Bank & Trust first reported a position in RCUS in Q3 2023 and held it in 1 quarter. The position peaked at $880 in Q3 2023. 185 funds tracked by Wall St. Rank hold RCUS as of Q4 2023.

Grove Bank & Trust reported no remaining Arcus Biosciences position as of Q4 2023 after selling out during the quarter.
Grove Bank & Trust sold 49 Arcus Biosciences shares in Q4 2023, an estimated $880.
Grove Bank & Trust first reported a position in Arcus Biosciences in Q3 2023 and held it in 1 quarter.
Grove Bank & Trust's Arcus Biosciences position peaked at $880 in Q3 2023.
185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2023.

Based on Grove Bank & Trust's 13F filing for Q4 2023, filed 30 Jan 2024.